Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings.

Abstract

The pathophysiologic basis for potent platelet inhibition in the acute coronary syndromes has been established. In the setting of PTCA for unstable angina and non-Q-wave myocardial infarction, there are clear data for a benefit of GP IIb/IIIa inhibition, whereas for primary PTCA in evolving myocardial infarction, preliminary data are very encouraging and a large-scale clinical trial is nearly completed. Glycoprotein IIb/IIIa inhibition as an adjunct to medical therapy for unstable angina is also the subject of encouraging preliminary data, and 3 large-scale clinical trials have just been completed. Preliminary data have also been accrued for GP IIb/IIIa inhibition as conjunctive therapy with thrombolytic agents, and large clinical trials are now commencing.

• Authors: N S Kleiman, A M Lincoff, E M Ohman, R A Harrington
• Journal: American heart journal (Am Heart J) Vol. 136 Issue 4 Pt 2 Su Pg. S32-42 (Oct 1998) ISSN: 0002-8703 [Print] United States
• PMID: 9778086 (Publication Type: Journal Article, Review)

Chemical References

• Platelet Aggregation Inhibitors
• Platelet Glycoprotein GPIIb-IIIa Complex

Topics

• Acute Disease
• Angina, Unstable (drug therapy, metabolism)
• Clinical Trials as Topic
• Coronary Disease (drug therapy, metabolism, physiopathology)
• Heart Conduction System (drug effects)
• Humans
• Myocardial Infarction (drug therapy, metabolism)
• Platelet Aggregation Inhibitors (therapeutic use)
• Platelet Glycoprotein GPIIb-IIIa Complex (antagonists & inhibitors, metabolism)
• Syndrome
• Thrombolytic Therapy